Congruence Therapeutics Funding: $140M Raised, Series B
Congruence Therapeutics is based in Montreal, Canada. It has raised $140M in total funding. Latest round: Series B.
Congruence Therapeutics funding overview
Congruence Therapeutics is based in Montreal, Canada. Congruence Therapeutics has raised $140M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in March 2026. The round record for Congruence Therapeutics runs through 2026; nothing later has been disclosed. Investors on record include OrbiMed, Dimension, Amplitude Ventures, Fonds de solidarité FTQ, Lumira Ventures, IQ and 4 others. 10 distinct backers are named across the disclosed rounds.
Frequently asked about Congruence Therapeutics funding
How much has Congruence Therapeutics raised?
Congruence Therapeutics has raised $140M in total disclosed funding across the rounds on record.
Who has invested in Congruence Therapeutics?
OrbiMed, Dimension, Amplitude Ventures, Fonds de solidarité FTQ, Lumira Ventures, IQ are named among the investors backing Congruence Therapeutics.
What was the latest Congruence Therapeutics funding round?
The most recent disclosed round is a Series B, announced in March 2026.
Where is Congruence Therapeutics based?
Congruence Therapeutics is based in Montreal, Canada.
When did Congruence Therapeutics last raise?
The last disclosed Congruence Therapeutics round closed in March 2026 at Series B.
Congruence Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Montreal below to benchmark round size and investor mix.
